Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (ανοίγει νέο παράθυρο)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Πηγή‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Καταχώριση‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (ανοίγει νέο παράθυρο)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (ανοίγει νέο παράθυρο)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Πηγή‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Καταχώριση‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (ανοίγει νέο παράθυρο)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (ανοίγει νέο παράθυρο)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Πηγή‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Καταχώριση‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (ανοίγει νέο παράθυρο)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (ανοίγει νέο παράθυρο)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Πηγή‎: Blood 2003;102(4):1529-30.

Καταχώριση‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (ανοίγει νέο παράθυρο)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (ανοίγει νέο παράθυρο)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Πηγή‎: Transfusion 2007;47(10):1830-6.

Καταχώριση‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (ανοίγει νέο παράθυρο)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (ανοίγει νέο παράθυρο)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Πηγή‎: Iran J Blood Cancer 2009;1(4):147-50.

Καταχώριση‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (ανοίγει νέο παράθυρο)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (ανοίγει νέο παράθυρο)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Πηγή‎: Int J Hematol 2012;95(1):51-6.

Καταχώριση‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (ανοίγει νέο παράθυρο)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (ανοίγει νέο παράθυρο)

Perrine SP.

Πηγή‎: Pediatr Ann 2008;37(5):339-46.

Καταχώριση‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (ανοίγει νέο παράθυρο)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (ανοίγει νέο παράθυρο)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Πηγή‎: Sci Rep. 2022;12(1):2752.

Καταχώριση‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (ανοίγει νέο παράθυρο)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (ανοίγει νέο παράθυρο)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Πηγή‎: Haematologica 2004;89(10):1172-8.

Καταχώριση‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (ανοίγει νέο παράθυρο)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (ανοίγει νέο παράθυρο)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Πηγή‎: Arch Iran Med 2009;12(3):295-7.

Καταχώριση‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (ανοίγει νέο παράθυρο)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (ανοίγει νέο παράθυρο)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Πηγή‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Καταχώριση‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (ανοίγει νέο παράθυρο)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (ανοίγει νέο παράθυρο)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Πηγή‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Καταχώριση‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (ανοίγει νέο παράθυρο)

Fetal globin gene inducers: novel agents and new potential. (ανοίγει νέο παράθυρο)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Πηγή‎: Ann N Y Acad Sci 2010;1202:158-64.

Καταχώριση‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (ανοίγει νέο παράθυρο)